Lutetium-177-PSMA bij gemetastaseerd prostaatcarcinoom

Larissa W. van Golen; Wouter Vogel; Marnix G.E.H. Lam

Lutetium-177-PSMA bij gemetastaseerd prostaatcarcinoom

Translated title of the contribution: Lutetium-177-PSMA in metastasized prostate carcinoma

Larissa W. van Golen
, Wouter Vogel
, Marnix G.E.H. Lam

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Lutetium-177 coupled with a ligand for Prostate Specific Membrane Antigen ([177Lu]Lu-PSMA) is a new treatment in The Netherlands. Patients with metastasized castration resistant prostate carcinoma and progressive disease after hormonal therapy and chemotherapy, and no other regular therapeutic options, can be referred. A good clinical performance state, adequate bone marrow function and a PSMA PET/CT showing adequate targeting in all metastases are essential. The therapy consists of four to six intravenous administrations of 7.4 GBq [177Lu]Lu-PSMA, six weeks apart. Side effects are mild and consist of xerostomia, fatigue and bone marrow depression. This therapy is currently administered only in a few hospitals in The Netherlands, mainly in research setting. An EMA registered product is expected at the end of 2022, which can contribute to better availability for reimbursed treatment.

Translated title of the contribution	Lutetium-177-PSMA in metastasized prostate carcinoma
Original language	Dutch
Article number	d6981
Journal	Nederlands Tijdschrift voor Geneeskunde
Volume	166
Publication status	Published - 16 Mar 2023

Keywords

Male
Humans
Positron Emission Tomography Computed Tomography
Prostate/pathology
Prostate-Specific Antigen
Dipeptides/adverse effects
Prostatic Neoplasms, Castration-Resistant/drug therapy
Treatment Outcome
Radiopharmaceuticals/adverse effects

Access to Document

d6981Final published version, 1.15 MBLicence: Taverne

Cite this

@article{fc21387ede8344ceaff88571b421ee6d,

title = "Lutetium-177-PSMA bij gemetastaseerd prostaatcarcinoom",

abstract = "Lutetium-177 coupled with a ligand for Prostate Specific Membrane Antigen ([177Lu]Lu-PSMA) is a new treatment in The Netherlands. Patients with metastasized castration resistant prostate carcinoma and progressive disease after hormonal therapy and chemotherapy, and no other regular therapeutic options, can be referred. A good clinical performance state, adequate bone marrow function and a PSMA PET/CT showing adequate targeting in all metastases are essential. The therapy consists of four to six intravenous administrations of 7.4 GBq [177Lu]Lu-PSMA, six weeks apart. Side effects are mild and consist of xerostomia, fatigue and bone marrow depression. This therapy is currently administered only in a few hospitals in The Netherlands, mainly in research setting. An EMA registered product is expected at the end of 2022, which can contribute to better availability for reimbursed treatment.",

keywords = "Male, Humans, Positron Emission Tomography Computed Tomography, Prostate/pathology, Prostate-Specific Antigen, Dipeptides/adverse effects, Prostatic Neoplasms, Castration-Resistant/drug therapy, Treatment Outcome, Radiopharmaceuticals/adverse effects",

author = "\{van Golen\}, \{Larissa W.\} and Wouter Vogel and Lam, \{Marnix G.E.H.\}",

year = "2023",

month = mar,

day = "16",

language = "Dutch",

volume = "166",

journal = "Nederlands Tijdschrift voor Geneeskunde",

issn = "0028-2162",

publisher = "Vereniging Nederlands Tijdschrift voor Geneeskunde",

}

TY - JOUR

T1 - Lutetium-177-PSMA bij gemetastaseerd prostaatcarcinoom

AU - van Golen, Larissa W.

AU - Vogel, Wouter

AU - Lam, Marnix G.E.H.

PY - 2023/3/16

Y1 - 2023/3/16

N2 - Lutetium-177 coupled with a ligand for Prostate Specific Membrane Antigen ([177Lu]Lu-PSMA) is a new treatment in The Netherlands. Patients with metastasized castration resistant prostate carcinoma and progressive disease after hormonal therapy and chemotherapy, and no other regular therapeutic options, can be referred. A good clinical performance state, adequate bone marrow function and a PSMA PET/CT showing adequate targeting in all metastases are essential. The therapy consists of four to six intravenous administrations of 7.4 GBq [177Lu]Lu-PSMA, six weeks apart. Side effects are mild and consist of xerostomia, fatigue and bone marrow depression. This therapy is currently administered only in a few hospitals in The Netherlands, mainly in research setting. An EMA registered product is expected at the end of 2022, which can contribute to better availability for reimbursed treatment.

AB - Lutetium-177 coupled with a ligand for Prostate Specific Membrane Antigen ([177Lu]Lu-PSMA) is a new treatment in The Netherlands. Patients with metastasized castration resistant prostate carcinoma and progressive disease after hormonal therapy and chemotherapy, and no other regular therapeutic options, can be referred. A good clinical performance state, adequate bone marrow function and a PSMA PET/CT showing adequate targeting in all metastases are essential. The therapy consists of four to six intravenous administrations of 7.4 GBq [177Lu]Lu-PSMA, six weeks apart. Side effects are mild and consist of xerostomia, fatigue and bone marrow depression. This therapy is currently administered only in a few hospitals in The Netherlands, mainly in research setting. An EMA registered product is expected at the end of 2022, which can contribute to better availability for reimbursed treatment.

KW - Male

KW - Humans

KW - Positron Emission Tomography Computed Tomography

KW - Prostate/pathology

KW - Prostate-Specific Antigen

KW - Dipeptides/adverse effects

KW - Prostatic Neoplasms, Castration-Resistant/drug therapy

KW - Treatment Outcome

KW - Radiopharmaceuticals/adverse effects

UR - https://www.scopus.com/pages/publications/85150312621

M3 - Article

C2 - 36943158

SN - 0028-2162

VL - 166

JO - Nederlands Tijdschrift voor Geneeskunde

JF - Nederlands Tijdschrift voor Geneeskunde

M1 - d6981

ER -

Lutetium-177-PSMA bij gemetastaseerd prostaatcarcinoom

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this